Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$10.25 USD

10.25
218,575

+0.04 (0.39%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $10.24 -0.01 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Best Momentum Stocks to Buy for July 15th

TBPH, HGV, and SPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2024.

New Strong Buy Stocks for July 15th

TEF, AY, CQP, TBPH, and VIRC have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2024.

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.

Here's Why You May Invest in Theravance (TBPH) Stock Now

Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.

Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know

The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates

Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 52.63% and 0.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -125% and 3.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates

Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.

Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 175% and 0.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates

Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of -65% and 1.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally

Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.

Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 18.75% and 9.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of 4% and 0.62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Is Theravance Bio (TBPH) Down 3.8% Since Last Earnings Report?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 11.11% and 24.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?